EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis

Shermin Chan, Karen Hon, Ruby E Dawson, Teresa Weng, Jelena Solujic, Yu C J Chey iD, James D Zuiani, Griffith B Perkins, P Toby Coates, Chris Drogemuller, Eddie Sanderlin, Lulu Huang und 6 weitere

British Journal of Pharmacology · 2026-08 · 183 (15) · 4126-4144

DOI: 10.1111/bph.70443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 22.04.2026. Verfasst von Shermin Chan und 17 weiteren Autor:innen. Beteiligte Einrichtung: South Australian immunoGENomics Cancer Institute (SAiGENCI), Adelaide University, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: ADAM17 Protein, Acute Lung Injury, Pancreatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tour de Cure, Cure Cancer Australia Postdoctoral, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Acute pancreatitis (AP) is a multifactorial upper gastrointestinal inflammatory disorder that in severe cases (~20% of all AP) is associated with substantial morbidity and mortality, the latter coincident with multiorgan dysfunction, particularly acute lung injury (ALI). Currently, there are no effective therapeutic agents to treat AP‐induced ALI. Experimental Approach The expression and function of the protease A Disintegrin and Metalloproteinase 17 (ADAM17) were investigated in two murine models of AP‐associated ALI induced by L‐arginine or cerulein (ceruletide). A human lung/pancreatic organoids co‐culture model of AP‐associated ALI was employed to validate ADAM17 up‐regulation in vitro . Key Results ADAM17 expression was up‐regulated in pancreatic and lung tissues of wild‐type (WT) mice exposed to AP‐associated ALI models. The genetic ( Adam17 ex/ex mice) and therapeutic (antisense oligonucleotides; ASOs) targeting of ADAM17 to reduce its expression in the lungs of mice ameliorated experimentally induced AP‐associated lung inflammation, which coincided with the selective reduction in the extracellular shedding of two ADAM17 substrates, soluble tumour necrosis factor α (TNFα) and soluble interleukin‐6 receptor (sIL‐6R). ADAM17 targeting in AP‐associated ALI also suppressed lung inflammatory cell infiltration, including macrophages, as well as cellular death in the lung alveolar compartment. Furthermore, ADAM17 expression was up‐regulated by L‐arginine or cerulein (ceruletide) in an in vitro human lung/pancreatic organoids co‐culture model of AP‐associated ALI. Conclusions and Implications Our findings indicate that the ADAM17 protease plays a crucial role in the pathogenesis of acute lung inflammatory responses during AP progression, which could pave the way for devising novel therapeutic options to treat AP‐induced ALI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAM17 ProteinAcute Lung InjuryPancreatitisAnimalsHumansMice, Inbred C57BLMiceMaleCeruletideDisease Models, AnimalTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

ADAM17acute lung injuryantisense oligonucleotidesinflammationpancreatitis

Substanzen

ADAM17 ProteinAdam17 protein, mouseADAM17 protein, humanCeruletideTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • South Australian immunoGENomics Cancer Institute (SAiGENCI), Adelaide University, Adelaide, SA, Australia.
  • Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.
  • Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.
  • Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
  • School of Medicine, College of Health, Adelaide University, Adelaide, SA, Australia.
  • Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia.

ORCID-Profile: Yu C J Chey, Mohamed I Saad

Förderung

  • Tour de Cure
  • Cure Cancer Australia Postdoctoral
  • National Health and Medical Research Council
  • International Association for the Study of Lung Cancer
  • Medical Research Future Fund
  • Cure Cancer Australia Foundation

Zitieren

APA

Chan, S., Hon, K., Dawson, R. E., Weng, T., Solujic, J., Chey, Y. C. J., Zuiani, J. D., Perkins, G. B., Coates, P. T., Drogemuller, C., Sanderlin, E., Huang, L., Finnie, J., Rose-John, S., Badiei, A., Nguyen, P., Jenkins, B. J., & Saad, M. I. (2026). The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis. British Journal of Pharmacology, 183(15), 4126-4144. https://doi.org/10.1111/bph.70443

Vancouver

Chan S, Hon K, Dawson RE, Weng T, Solujic J, Chey YCJ, et al. The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis. British Journal of Pharmacology. 2026;183(15):4126-4144. doi:10.1111/bph.70443

BibTeX
@article{Chan2026,
  author = {Chan, Shermin and Hon, Karen and Dawson, Ruby E and Weng, Teresa and Solujic, Jelena and Chey, Yu C J and Zuiani, James D and Perkins, Griffith B and Coates, P Toby and Drogemuller, Chris and Sanderlin, Eddie and Huang, Lulu and Finnie, John and Rose-John, Stefan and Badiei, Arash and Nguyen, Phan and Jenkins, Brendan J and Saad, Mohamed I},
  title = {The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4126--4144},
  doi = {10.1111/bph.70443}
}
Kostenlos starten →